Anzeige
Mehr »
Login
Donnerstag, 25.02.2021 Börsentäglich über 12.000 News von 656 internationalen Medien
Adhoc-Meldung: Eine ganz große Überraschung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A143G8 ISIN: FR0013018124 Ticker-Symbol: NXOA 
Tradegate
24.02.21
16:56 Uhr
4,530 Euro
+0,035
+0,78 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
NICOX SA Chart 1 Jahr
5-Tage-Chart
NICOX SA 5-Tage-Chart
RealtimeGeldBriefZeit
4,4654,51523:00
4,4454,48022:00
GlobeNewswire (Europe)
269 Leser
Artikel bewerten:
(1)

Nicox Analyst Coverage Initiated by Edison Investment Research

Press Release
Nicox Analyst Coverage Initiated by Edison Investment Research


January 22, 2021 - release at 7:30 am CET
Sophia Antipolis, France



Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that Edison, an investment research and advisory company with a world-renowned equity research platform and deep international healthcare expertise, has initiated equity research coverage of Nicox.



The financial report by Edison, released on January 21, 2021, is available on the Edison website https://www.edisongroup.com/publication/focus-on-sight/28664 (https://www.edisongroup.com/publication/focus-on-sight/28664).



Nicox is also covered by Bryan, Garnier & Co. and Kepler Cheuvreux in France, and H.C Wainwright & Co., Oppenheimer & Co. Inc. and Cantor Fitzgerald in the U.S.



Michele Garufi, Chairman and CEO of Nicox, will present at the Edison Open House Global Healthcare Conference 2021 being held virtually on January 26-28, 2021. The video webcast of Nicox's presentation will be available on-demand by clicking here (https://www.lsegissuerservices.com/spark/healthcare-companies-presenting-edison-open-house) and accessible on Nicox's website (www.nicox.com (http://www.nicox.com)) in the "Presentations & Events" section.


About Nicox
Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets.

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com (http://www.nicox.com).
Analyst coverage


Bryan, Garnier & Co Victor Floc'h Paris, France
Cantor Fitzgerald Louise Chen New York, U.S.
Edison Pooya Hemami London, U.K.
H.C. Wainwright & Co Yi Chen New York, U.S.
Kepler Cheuvreux Damien Choplain Paris, France
Oppenheimer & Co Hartaj Singh New York, U.S.
The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Contacts
Nicox
Gavin Spencer
Executive Vice President, Chief Business Officer
& Head of Corporate Development
T +33 (0)4 97 24 53 00
communications@nicox.com (mailto:communications@nicox.com)
Investors & Media
United States & Europe
LifeSci Advisors, LLC
Mary-Ann Chang
T +44 7483 284 853
mchang@lifesciadvisors.com (mailto:mchang@lifesciadvisors.com)
Media
France
LifeSci Advisors, LLC
Sophie Baumont
M +33 (0)6 27 74 74 49
sophie@lifesciadvisors.com (mailto:sophie@lifesciadvisors.com)
Forward-Looking Statements
The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 3rd chapter of the 'Document d'enregistrement universel, rapport financier annuel et rapport de gestion 2019' filed with the French Autorité des Marchés Financiers (AMF) on March 6, 2020 which is available on Nicox's website (www.nicox.com (http://www.nicox.com)) and in the 4th chapter of the half yearly financial report as of June 30, 2020, which is also available on Nicox's website..
Nicox S.A.
Drakkar 2
Bât D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99

Attachment

  • EN_Edison Nicox Initiation PR_20210122_F1 (https://ml-eu.globenewswire.com/Resource/Download/5852def1-618d-4229-9483-709b84858320)

NICOX-Aktie komplett kostenlos handeln - auf Smartbroker.de
© 2021 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.